Global Biotech
Intelligence.

Driven by the launch of the Human Genome Project and early genomics tools, venture capital flowed into startups aiming to map and sequence genes. The era was characterized by high-risk, long-term bets on platform technologies, culminating in high-profile IPOs like Genentech's, though many companies struggled to translate discoveries into products.

The completion of the first human genome draft in 2000 sparked a funding boom, but the dot-com crash and high-profile clinical failures led to a severe downturn. VC funding became more cautious, shifting focus towards later-stage companies with clearer paths to market, aiding a gradual recovery by the mid-2000s.

The 2008 global financial crisis froze biotech VC funding, forcing a wave of consolidations and shutdowns. The recovery was slow and selective, driven by the 2010 JOBS Act and a growing interest in capital-efficient platforms like monoclonal antibodies, which began to demonstrate clinical and commercial success.

Unprecedented VC investment surged into novel modalities, fueled by breakthroughs in immunotherapy (CAR-T), gene therapy (Luxturna approval), and CRISPR gene editing. A robust IPO window and high-profile acquisitions validated the sector, attracting significant crossover investment from public market funds.

The COVID-19 pandemic triggered a historic funding boom, with massive investment in mRNA platforms and diagnostics, leading to record IPOs and valuations. This was followed by a sharp market correction starting in 2021, as rising interest rates and macroeconomic pressures returned investor focus to profitability and clinical data over speculative growth.